Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine
- Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trial
- Clinical responses seen in patients with favored and less favored baseline characteristics
- T cell activation observed post-treatment in tumors of responding patients
Oslo, September12, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for the treatment of cancer, announced today the publication of data from its phase I melanoma trial in Journal of Translational Medicine.
The clinical data give details of potential additional benefit in the treatment of patients with malignant melanoma from using the company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor ipilimumab.
The new data demonstrated highly positive clinical outcome signals. Vaccine-induced immune responses were apparent in 91% of evaluable patients, with strong T cell proliferation demonstrated in peripheral blood, and vaccine-related T cell receptor clones detected in blood and in tumor biopsy. Patients who responded clinically to treatment with UV1 and ipilimumab, also demonstrated an increase in the tumor interferon-gamma signature, a generally accepted predictor for the efficacy of checkpoint inhibitors.
The research team observed clinical responses to the UV1-ipilimumab combination not only in patients with baseline characteristics of high tumor immunogenicity (‘hot’ tumors) but also in patients without (‘cold’ tumors). This breadth of response is noteworthy since ’cold’ tumors are more difficult to treat with checkpoint inhibitors, suggesting that the addition of UV1 vaccination may extend clinical efficacy against these tumor types.
These clinical data further expand upon the previously published safety and feasibility findings from an open-label phase 1/2a clinical trial (NCT02275416) of the combination of UV1 with the CTLA-4 checkpoint inhibitor, ipilimumab. The combination of UV1 and ipilimumab produced an overall response rate (ORR) of 33%. The median progression-free survival (mPFS) among patients treated with UV1 and ipilimumab was 6.7 months, and the median overall survival (mOS) was 66.3 months.
Ultimovacs’ phase II trial, INITIUM, evaluates the combination of the UV1 vaccine combined with both ipilimumab and the PD-1 inhibitor, nivolumab, in the first-line treatment of patients with advanced malignant melanoma. Ultimovacs completed enrollment in INITIUM in June 2022. Topline progression-free survival data from INITIUM are expected in H1 2023.
The new data were published in the Journal of Translational Medicine (JTRM), an open access, peer-reviewed journal. The link to the article can be found on the Company’s website.
Ellingsen, E.B., Bounova, G., Kerzeli, I. et al. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. J Transl Med 20, 419 (2022). https://doi.org/10.1186/s12967-022-03624-z
About the phase I trial with UV1 and ipilimumab in malignant melanoma
This clinical trial evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, in twelve patients with metastatic melanoma. The trial was an open-label, single-center phase I/IIa study. Eligible patients had unresectable metastatic melanoma. Patients were followed up for progression-free survival (PFS) and overall survival (OS).
The U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for UV1 for the treatment of stage IIB – IV melanoma, and Fast Track designation in the treatment of unresectable or metastatic melanoma – either as add-on therapy to pembrolizumab or as add-on therapy to ipilimumab. Ultimovacs is currently evaluating UV1 as add-on therapy to ipilimumab and nivolumab as first-line treatment for unresectable or metastatic melanoma in a Phase II study named INITIUM.
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program in five cancer indications enrolling more than 650 patients, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types, in combination with other immunotherapies, for patients with unmet needs. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Phone: +47 908 92507
Anne Worsøe, Head of Investor Relations
Phone: +47 906 86 815
Mary-Ann Chang, LifeSci Advisors
Phone: +44 7483 284 853
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
EPH European Property Holdings PLC - Notice of Extraordinary General Meeting7.10.2022 19:00:00 CEST | Press release
7 October 2022, Nicosia, Cyprus I Ad hoc announcement pursuant to Art. 53 LR NOTICE IS HEREBY GIVEN THAT an Extraordinary General Meeting of EPH EUROPEAN PROPERTY HOLDINGS PLC (the “Company” or “EPH”) will be held on 1st November 2022 at 11 AM at Hotel Four Seasons Hotel Limassol, 67-69 Amathountos Avenue, Ag. Tychonas, 4532 Limassol, Cyprus, FOR THE FOLLOWING PURPOSES: APPROVAL OF SALE OF EPH GROUPS’ RUSSIAN PORTFOLIO The uncertainty over the future economic and political developments as well as the Russian economy have led the Board of Directors to the conclusion to ask the Company’s shareholders for approval of the sale of the entire Russian property portfolio within the framework of a management buy-out. The sale involves six rental properties and Arbat apartments in Moscow together with their holding companies domiciled in Cyprus and Germany, which account for around 40% of EPH’s total asset value. The basis for the purchase price consideration will be the market values of the Rus
Nordic American Tankers Ltd (NYSE: NAT) – 2022 Annual General Meeting of Shareholders (AGM)7.10.2022 14:30:00 CEST | Press release
Friday, October 7, 2022 Dear Shareholders and Investors, In our press release of June 7, 2022, we informed you about the date of the 2022 Annual General Meeting (AGM) in Nordic American Tankers Limited (NAT). The date has been set to November 17, 2022. Please be informed that the record date is September 26, 2022, for the determination of the NAT shareholders entitled to receive notice of and to vote at the AGM or any adjournment thereof. The Notice of the Meeting and Proxy Statement will be available with the Securities and Exchange Commission (SEC) on a form 6-K today, October 7, 2022. The AGM will take place in Monaco. For contacts, please see at the end of this communication. Best regards, Herbjorn Hansson Founder, Chairman & CEO Nordic American Tankers Ltd. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections
The order to supply all mineral processing technologies for ShalkiyaZinc’s greenfield zinc-lead concentrator in Kazakhstan becomes effective7.10.2022 14:27:54 CEST | Press release
COMPANY ANNOUNCEMENT NO. 16-2022 The previously announced signed contract to supply all mineral processing technology to ShalkiyaZinc, the operator of a zinc and lead mine in the Kyzylorda Region, located in the south of Kazakhstan (refer to Company Announcement No. 12-2022), is now effective. The contract is valued at around DKK 950 million and will be part of the Q4 2022 order intake. The equipment delivery is to be completed during 2024, with commissioning to start before the end of that year. The new plant will be a world-class production facility that efficiently separates the minerals with a minimised environmental impact. As detailed in the order announcement in August 2022, FLSmidth will supply two underground crushing stations with a materials handling system to the process plant, a full package of comminution and separation equipment. This includes SAG and ball mills, mill circuit pumps and cyclones, the zinc-lead concentrate flotation and regrinding circuit, including nextST
Program for the publication of Yara International ASA third quarter results 20227.10.2022 11:05:00 CEST | Press release
The Yara International ASA third quarter 2022 results will be published on Thursday20October 2022at08:00 CEST. An on-line presentation will be held at 12:00 CEST, hosted by Yara President and CEO Svein Tore Holsether. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at: yara.com/investor-relations/latest-quarterly-report/ There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management. Please use this link to register for this session: https://registrations.events/direct/Q4E60136. Registered participants will receive a full list of available international dial-in numbers and a unique passcode upon completed registration. Please join the event 5-10 minutes prior to scheduled start time. Alternatively, it is possible to use the dial-in numbers listed below on the day of the conference call to register through an operator: Norway - National +18.104.22.168.30
Telenor etablerer fiberselskap i Norge7.10.2022 08:55:29 CEST | Pressemelding
(Fornebu 07 september 2022) Telenor inngår en transaksjon som skal støtte fremtidige investeringer i Norges telekominfrastruktur. Tidligere i år påbegynte Telenor en prosess for å vurdere etableringen av et eierselskap for passiv fiberinfrastruktur, med en medinvestor i en minoritetsposisjon. Telenor har nå kommet til enighet om å selge 30 prosent av det nye fiberselskapet til et konsortium ledet av det globale investeringsselskapet KKR, som investerer gjennom sin kjerneinfrastrukturstrategi. Konsortiet inkluderer Oslo Pensjonsforsikring som medinvestor. Det nyetablerte selskapet er et datterselskap av Telenor og vil bli en del av det nye forretningsområdet Telenor Infrastruktur. Selskapet vil eie de passive elementene i det norske fibernettet. Dette omfatter omtrent 130.000 kilometer med kabler som leverer tjenester til omtrent 560.000 husstander. Eiendelene vil bli skilt ut fra Telenor Norge før transaksjonen sluttføres. Telenor Norge blir selskapets eneste kunde og alle operasjonell